Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the strong heart study. by de Simone G et al.
Left ventricular mass and incident hypertension in individuals
with initial optimal blood pressure:
The Strong Heart Study
Giovanni de Simonea,b, Richard B. Devereuxa, Marcello Chinalib, Mary J. Romana, Thomas
K. Weltyc, Elisa T. Leed, and Barbara V. Howarde
aWeill-Cornell Medical College, New York, New York, USA
bFederico II University Hospital, Naples, Italy
cMissouri Breaks Industry Research, Timber Lake, South Dakota
dUniversity of Oklahoma, Oklahoma City, Oklahoma
eMedstar Research Institute, Washington, District of Columbia, USA
Abstract
Objective—Metabolic abnormalities have been shown to predict 8-year incident arterial
hypertension in individuals with optimal blood pressure. As echocardiographic left ventricular mass
has also been reported to predict incident hypertension in individuals with baseline blood pressure
of less than 140/90 mmHg, we determined whether left ventricular mass predicts 4-year incident
hypertension also in individuals with initial optimal blood pressure (<120/80 mmHg), independent
of metabolic factors influencing blood pressure.
Methods—We studied 777 of 3257 members of the American Indian population-based Strong Heart
Study cohort with optimal blood pressure (34% men, 45% obese, and 35% diabetic), aged 57 ± 7
years, and without prevalent cardiovascular disease.
Results—Over 4 years, 159 individuals (20%, group H) developed hypertension (blood pressure
≥140/90 mmHg). They had a greater baseline BMI, waist girth, and blood pressure (112/69 vs. 109/68
mmHg, all P<0.03) than those remaining normotensive (group N), with similar lipid profile and renal
function. At baseline, left ventricular mass was significantly greater in group H than in group N
(P<0.004). The difference in left ventricular mass was confirmed after controlling for initial BMI,
systolic blood pressure, homeostatic model assessment index, and diabetes. The probability of
incident hypertension increased by 36% for each standard deviation of left ventricular mass index
(P=0.006), independent of covariates. Participants with left ventricular mass of more than 159 g (75th
percentile of distribution) had 2.5-fold (95% confidence interval, 1.4-3.6; P<0.001) higher adjusted
risk of incident hypertension than those below this value.
Conclusion—Left ventricular mass predicts incident arterial hypertension in individuals with
initially optimal blood pressure. This association is independent of body build, prevalent diabetes,
and initial blood pressure.
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Arterial hypertension is a complex, multifactorial hemodynamic condition driven by a variety
of diseases and abnormalities of cardiovascular homeostasis, making it difficult to prevent its
development and reduce its incidence by interventions on single aspects [1-4]. Metabolic risk
factors, including obesity, dyslipidemia, and impaired glucose metabolism, can have vascular
and hemodynamic effects that ultimately contribute to the development of arterial hypertension
[5-7]. There is also evidence that unfavorable changes in these factors over time can potentiate
the development of arterial hypertension [7]. Those associations, however, do not clarify why
some but not other individuals exposed to these risk factors develop arterial hypertension.
Genetic factors, acting through different pathways, may contribute to the development of
hypertension [1,8-10]. Several earlier studies suggested that higher left ventricular (LV) mass
in normotensive individuals can predict subsequent hypertension [11-13], an observation that
revitalized the concept that a more forceful cardiac pump could contribute to the development
of high blood pressure (BP) in the presence of an arterial tree unable to either reduce peripheral
resistance or increase conduit artery compliance or both [14]. Unfortunately, previous studies
were conducted in population samples with normal or high-normal BP, but not optimal BP.
Thus, they could not answer the question of whether the association between LV mass and
incident hypertension was driven by initial BP in the range classified today as high-normal or
prehypertensive, which may have already caused altered cardiac structure and function [15].
Whether LV mass is associated with the development of arterial hypertension in the presence
of initial optimal BP is, therefore, unknown. Accordingly, the present study was designed to
determine whether, in the presence of optimal baseline BP, a higher LV mass predicts incident
arterial hypertension, independent of established cardiovascular risk factors.
Methods
Population
The Strong Heart Study (SHS) is a population-based longitudinal cohort study of
cardiovascular risk factors and disease in American Indians from communities in Arizona,
Southwestern Oklahoma and South and North Dakota, as extensively described [16-20].
During the second examination, in the years 1993-1996, participants also underwent a standard
transthoracic echocardiographic study. Those with available information on body size and fat
distribution, diabetes status, lipid profile, BP, and LV mass were first selected for the present
analysis (n=3257). Participants with prevalent cardiovascular disease, including stroke,
congestive heart failure, myocardial infarction, and other manifestations of coronary heart
disease (assessed by coronary angiography or a combination of typical symptoms with positive
treadmill tests or abnormal imaging stress test, or need for revascularization procedures), were
excluded (n=394). Prevalent cardiovascular events were confirmed by the Strong Heart Study
Mortality and Morbidity Committees, using specified criteria for causes of fatal and non-fatal
cardiovascular events [21]. Diabetic and obese participants were included; however, similar
to the criteria previously reported [7], only untreated participants with optimal baseline BP
(<120/80 mmHg) [22-24] were included in the studied population sample. Thus, after
exclusions, 777 participants with an optimal baseline BP at the time of the second SHS
examination (261 men or 33.6%) and with a mean age of 57±7 years were considered in the
present analysis.
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Laboratory tests and classification of participants
BP measurements were accurately standardized in the SHS [25]. Briefly, BP was measured in
the sitting position after a 5-min rest. After the first measurement, another two measurements
were taken after raising the arm for 5 s and resting it on the table for another 25 s. The last two
measurements were averaged to generate the reported BP value.
Fasting plasma glucose and lipid profile were measured by standard methods [18]. Diabetes
was diagnosed by 1997 American Diabetes Association recommendations [26]. Homeostatic
model assessment (HOMA) index was used to estimate insulin resistance [27]. Obesity was
identified by BMI of at least 30 kg/m2 based on 1998 National Institutes of Health (NIH)
guidelines [28]. Waist circumference was used as an indicator of central adiposity according
to 1998 NIH guidelines [28]. Glomerular filtration rate (GFR) was estimated by the simplified
modification of diet in renal disease (MDRD) formula [29].
Echocardiographic measures
Measurements of interventricular and posterior wall thickness, and LV diastolic internal
diameter, were taken using M-mode tracings or linear two-dimensional measures taken from
the parasternal long axis view according to a well standardized method [30-32]. LV mass was
calculated by a necropsy validated formula [33] and was normalized for body surface area and
height2.7 [34]. Left ventricular hypertrophy (LVH) was defined according to population-
specific partition values (47.24 g/m2.7), which have been prognostically validated [34].
Statistical analysis
Data were analyzed using SPSS 12.0 software (SPSS Inc, Chicago, Illinois, USA). Data are
expressed as mean±one standard deviation (SD). Indicator variables were included in all
multivariate analyses for the three field centers, Arizona, South/North Dakota, and Oklahoma.
Incident hypertension was defined either as BP of at least 140 mmHg or 90 mmHg or both, or
ongoing antihypertensive treatment at the time of the third SHS examination 46±9 months after
the second examination. Descriptive statistics were obtained by one-factor analysis of variance
(ANOVA) or χ2 distribution. Changes over time of potential metabolic predictors of arterial
hypertension were compared between the groups with or without incident hypertension by
analysis of covariance (ANCOVA) for repeated measures, adjusting for age and sex. Adjusted
means are displayed. The main potential confounders associated with follow-up hypertension
were evaluated in binary logistic regression models. To evaluate whether LV mass index
significantly added to the prediction of incident hypertension obtained with the main factors,
a hierarchical model was generated by entering a primary block of main covariates, including
age, sex, systolic blood pressure, BMI, diabetes, and HOMA index. LV mass index was,
therefore, added to the primary model (secondary block). Likelihood functions were compared
between the models without or with LV mass index [35]. The difference between the two
likelihood functions has a χ2 distribution, which, for this comparison, has one degree of freedom
(i.e. one variable added to the model) [35].
Results
At the time of the second examination, 44.5% of the 777 participants were obese (50% of
women and 33% of men) and diabetes was present in 34.7% of participants (38% of women
and 28% of men, both P<0.0001).
By the time of the third SHS examination, incident arterial hypertension had developed in 159
participants (20% of men and 21% of women), 98 of whom (62%) were on medications. At
baseline, participants developing hypertension during the follow-up were slightly more obese
(P<0.02), had 3 mmHg higher average systolic BP with borderline higher diastolic BP; they
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also had higher plasma glucose and HOMA index, and prevalence of diabetes, than participants
maintaining normal BP (Table 1; all P<0.0001). No differences were found between groups
in lipid profile, GFR, or heart rate. LVH was found in 62 participants (8%) and was 1.97-fold
more prevalent among participants who developed hypertension than among those remaining
normotensive [95% confidence interval (CI), 1.12-3.47; P<0.03].
Table 2 shows changes between the time of the second (baseline) and the third SHS examination
in the metabolic profile of participants with or without hypertension detected at the time of the
third SHS examination. Body weight increased in the entire population sample during follow-
up. Adjusting for age and sex, individuals developing hypertension gained slightly more weight
than those remaining normotensive (P<0.03). During follow-up, plasma glucose decreased
significantly in the group developing hypertension (P<0.002), due to the effect of treatment of
diabetes detected during the second examination, but remained higher than in those with
persistent normal BP. No significant differences were detected in changes of lipid profile or
GFR.
Baseline left ventricular geometry
At baseline, LV mass was higher in participants developing hypertension than in those
remaining normotensive, in absolute terms and after normalization for body size (Table 3; all
P<0.0001). Because the LV mass difference could be due to differences in clinical and
metabolic factors (Tables 1 and 2), the comparison was repeated with adjustment for baseline
systolic BP, BMI, HOMA index, and presence of diabetes. Table 3 also shows the adjusted
means of baseline LV mass by different types of normalization for body size in participants
with or without follow-up hypertension. Initial LV mass remained higher in participants
developing arterial hypertension, irrespective of the method used to normalize for body size
and after adjustment for main confounders.
Prediction of incident hypertension
After adjusting for sex, baseline BMI, systolic BP, HOMA index, and presence of diabetes or
impaired fasting glucose, the probability of developing arterial hypertension over a 4-year
follow-up increased by 39% for each 7.9 g/m2.7 (corresponding to one SD in the whole
population sample) of initial LV mass index [relative risk (RR), 1.39/7.9g/m-2.7 (1.11-1.73,
P=0.004)]. In addition to the LV mass index, higher initial systolic BP [RR, 1.07/mmHg
(1.03-1.10; P<0.0001)] and presence of diabetes [RR, 2.59 (1.43-4.70; P=0.002)] were also
independent predictors of incident hypertension, whereas no effect was found for HOMA
index, BMI, and impaired fasting glucose.
Because of the significant effect of diabetes in the prediction of subsequent hypertension,
diabetic and non-diabetic participants were also separately analyzed. LV mass index was
significantly higher in the presence of diabetes (38.08±7.59 vs. 36.18±7.70 g/m2.7; P<0.02,
adjusted for systolic BP) and was confirmed as a predictor of incident hypertension in
nondiabetic participants [RR, 1.84/7.9g/m-2.7 (1.35-2.51; P<0.0001)] independent of the
significant effect of systolic BP [RR, 1.06/mmHg (1.02-1.12; P=0.009)], without other
significant contributions from sex, BMI, and HOMA index. In contrast, among diabetic
participants, the only significant independent predictor of incident hypertension remained
initial BP [RR, 1.07/mmHg (1.02-1.12; P=0.004)].
To examine whether the addition of LV mass index improved the prediction of incident
hypertension in the whole population, we also used the χ2 distribution to compare the likelihood
functions of the model including all covariates but excluding LV mass index with the same
model into which LV mass index was forced on the top of the primary variables. The -2log
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likelihood function was 592 in the model without LV mass and 583 in the model including LV
mass, a difference that was statistically significant (P<0.005).
Figure 1 shows the progressively higher likelihood of developing hypertension in progressively
higher deciles of LV mass/height2.7 obtained from the resulting functions from the logistic
regression model. Participants in the highest decile of the distribution had a more than 30%
likelihood of developing hypertension in the next 4 years. Participants with LV mass higher
than the 75th percentile of the distribution in the SHS cohort (159 g) had a 2.5-foldhigher
adjusted risk of developing arterial hypertension (1.42-3.60, P<0.0005) in the next 4 years than
participants with LV mass 159 g or less, independent of the covariates used in the logistic
regression model.
Discussion
The possibility that LV mass predicts future hypertension has been already reported in studies
in relatively unselected populations [11-13] and in children with a family history of
hypertension [36]. However, the entry criteria of those studies reflected old classifications of
BP (i.e. <140/90 mmHg) [11,13] that included participants with high-normal and
prehypertensive BP in the normotensive group [24,37]. According to recent guidelines, normal
(optimal) BP values should be below 120/80 mmHg. Clinical evidence of optimal BP might
be reasonably considered to confer a low risk of future high BP. In addition, in all the previous
studies, LV mass was measured using only M-mode echocardiograms, a method that results
in the exclusion of a large number of individuals due to body size, age, and other factors [38],
whereas the combined M-mode and 2D approach used in the SHS allows measurement of LV
mass in almost all participants, even if most are obese [38].
Thus, the present study is the first prospective analysis examining whether initial values of LV
mass are associated with incident hypertension in a population-based cohort of individuals with
initial optimal BP values and a broad range of body size and related metabolic abnormalities.
Our analysis demonstrated that even when BP is optimal, the magnitude of LV mass measured
by transthoracic echocardiography strongly predicts the probability of incident arterial
hypertension.
Although BP is a pathophysiological continuum, from the practical standpoint, the evidence
that LV mass is still a predictor of hypertension when the baseline variability of BP is
constrained to the optimal range and, therefore, substantially limited (the coefficient of
variability of systolic BP was as low as 7%) is relevant. In addition, unlike previous studies
[11], our analysis also considered metabolic risk factors that others and we [5-7] have shown
to be associated with the rise of BP over time, probably due to the progressive alteration of the
arterial tree due to atherosclerosis. The conservative hierarchical approach we have used,
giving LV mass a secondary value in the regression model compared with BP, body weight
and abnormal glucose metabolism, confirmed that LV mass significantly adds to the prediction
of 4-year incident hypertension obtained with the factors used as primary predictors. This result
was also consistent in analyses with absolute values of LV mass or LV mass normalized for
different measures of body size. Interestingly, the effect was substantially driven by the
nondiabetic population with lower levels of LV mass, and therefore, with a more identifiable
association than the subgroup with diabetes, which already presents with a more severe
impairment of the cardiovascular system (33% of diabetic participants developed hypertension
as compared with 14% of nondiabetic participants, independent of LV mass).
There are possible explanations of our findings. The SHS population has a high prevalence of
central obesity [39], and masked hypertension is found more frequently in patients with central
obesity [40]. In our study, arterial hypertension has been detected using office and not
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ambulatory BP. Thus, the possibility that at least some participants with incident office arterial
hypertension could have had masked hypertension [40] at the time of initial examination could
not be ruled out. The prevalence of masked hypertension is reported to be about 10% in
unselected populations [41,42]. This would imply that 70-80 participants in our study could
have had masked hypertension. In addition, because of the variability of BP in day to day
measures, there is also the possibility that the higher LV mass reflects a prolonged sustained
exposure to higher BP, which cannot be captured by single office measurements, even if taken
with a very standardized protocol. This has also been recently suggested by Kokkinos et al.
[43] who reported that a change in BP from rest to five metabolic equivalents (i.e. a workload
corresponding to most daily activities) is the strongest predictor of LV hypertrophy, whereas
fitness protects from an excessive rise of BP during activity [44].
Although the above explanation is simple and plausible, this study also supports the possibility
of reverse causation, not necessarily alternative to the possibility that some or many of our
participants had masked hypertension. The concept that the power developed by the heart
represents one of the mechanisms responsible for the increase in BP is supported by the
evidence that hypertension can be predicted by the increase in BP during exercise. This
exercise-induced increase in BP is in turn associated with a high LV mass [45], a finding that
parallels the detection of masked hypertension by ambulatory monitoring during daily
activities, a time when the blood supply requirements are higher than during the resting
conditions at the office visit [46,47]. An equilibrium among pump force, circulating flow,
conduit artery compliance and elasticity and peripheral resistance to blood flow is a requisite
for the circulatory system to maintain fluid pressure [48-50]. Thus, the development of arterial
hypertension requires a convergence of alterations of different factors, including
cardiovascular musculature, heart strength and magnitude of circulating volume, which result
in BP augmentation when the elasticity of conduit arteries and peripheral resistance are
impaired by the adverse effect of atherogenic risk factors, all elements that can be found in our
analyses [7].
In our previous study [7], abdominal obesity and its progression were strongly associated with
8-year incident arterial hypertension, despite the relatively small range of variability of these
parameters in this population, consistent with the evidence that obesity and the associated
neurohormonal patterns are well documented predictors of future hypertension in
epidemiological and clinical studies [51,52]. In the present shorter follow-up, obesity and a
higher BMI were also associated with incident hypertension in univariate analysis, but their
effect in the model was obscured by other cofactors, including LV mass index, suggesting that
an increased LV mass might integrate at least a part of the effect of alteration of body size on
incident hypertension. This finding is also in line with previous evidence that genes common
to LV mass and body weight significantly influence their covariance and that as much as 90%
of the LV mass-body weight relation might be due to common genes [53].
In conclusion, we provide evidence that LV mass is a predictor of 4-year incident arterial
hypertension in a population-based sample with high prevalence of obesity but initial optimal
BP. This prediction is independent of metabolic and anthropometric factors already
demonstrated to be associated with incident hypertension.
The possibility to refine the identification of a phenotype at high risk of arterial hypertension,
by pooling metabolic information with the measure of LV mass, increases the chance to target
individuals that might benefit from preventive treatment, as already proposed for high-normal
BP values. Further research is needed to quantify the possible impact of masked hypertension
on the association between LV mass and incident office hypertension and clarify their cause-
effect relationship.
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Fig. 1.
Adjusted probability of 4-year incident hypertension in relation to initial deciles of left
ventricular mass index. LVMI, left ventricular mass index.
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